Skip to main content

ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2023 Operating Results

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Monday, July 31, 2023 to discuss its second quarter 2023 operating results. Management will also provide a brief update on the business.

CONFERENCE CALL INFORMATION

To access the live call by phone, please register here. A dial-in and unique PIN will be provided to join the call. The call may also be accessed through the Investors and Media section of the Company’s website, www.immunogen.com. Following the call, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  220.30
+3.82 (1.76%)
AAPL  263.90
+1.66 (0.63%)
AMD  238.02
-2.54 (-1.06%)
BAC  52.17
+0.13 (0.25%)
GOOG  253.17
-3.85 (-1.50%)
META  733.09
+0.92 (0.13%)
MSFT  517.89
+1.10 (0.21%)
NVDA  180.90
-1.74 (-0.95%)
ORCL  275.19
-2.00 (-0.72%)
TSLA  442.55
-4.88 (-1.09%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.